U.S. Markets close in 6 hrs 19 mins
  • S&P 500

    4,233.45
    +26.18 (+0.62%)
     
  • Dow 30

    33,509.61
    +172.94 (+0.52%)
     
  • Nasdaq

    12,873.19
    +93.28 (+0.73%)
     
  • Russell 2000

    1,975.26
    +6.01 (+0.31%)
     
  • Crude Oil

    92.50
    -1.84 (-1.95%)
     
  • Gold

    1,809.50
    +2.30 (+0.13%)
     
  • Silver

    20.37
    +0.02 (+0.10%)
     
  • EUR/USD

    1.0276
    -0.0049 (-0.4727%)
     
  • 10-Yr Bond

    2.8400
    -0.0480 (-1.66%)
     
  • Vix

    19.86
    +0.12 (+0.61%)
     
  • GBP/USD

    1.2117
    -0.0085 (-0.6968%)
     
  • USD/JPY

    133.6570
    +0.6580 (+0.4947%)
     
  • BTC-USD

    23,780.60
    -815.98 (-3.32%)
     
  • CMC Crypto 200

    564.86
    -6.42 (-1.12%)
     
  • FTSE 100

    7,487.17
    +21.26 (+0.28%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

Why Tyme Technologies's Stock Is Trading Higher Today

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Tyme Technologies (NASDAQ: TYME) shares are trading higher on Monday after the company announced an orphan drug designation for its SM-88 as a potential treatment for patients with pancreatic cancer.

Tyme Technologies is a U.S.-based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans.

SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.

Tyme Technologies shares were trading up 14.29% to $1.36 at time of publication on Monday. The stock has a 52-week high of $2.04 and a 52-week low of 86 cents.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.